Back to Directory

Filgrastim

Performance & Endurance

G-CSF for stimulating neutrophil production, prevents infection after chemotherapy.

Key Benefits

  • ✓Increases neutrophils
  • ✓Reduces infection risk
  • ✓Post-chemotherapy support
  • ✓Mobilizes stem cells
  • ✓Treats chronic neutropenia

Dosing Information

Dosage Range
5 mcg/kg
Frequency
Once daily
Typical Duration
10-14 days or until recovery

Detailed Protocol

Administered via subcutaneous injection daily, typically starting 24 hours after chemotherapy until neutrophil recovery. Can be self-administered after training. Prescription only.

About Filgrastim

Filgrastim (Neupogen) is recombinant human granulocyte colony-stimulating factor (G-CSF). Stimulates neutrophil production and release. FDA-approved to reduce infection risk from chemotherapy-induced neutropenia and other indications.

Research Notes

FDA-approved in 1991, first G-CSF. Revolutionized cancer care by reducing infection risk. Widely used in oncology. Biosimilars available. Standard supportive care.

Get Peptide Research Updates

Newsletter signup

Please wait...

Thanks for signing up! You will receive an email to confirm your subscription.

Potential Side Effects

  • •Bone pain (very common)
  • •Injection site reactions
  • •Splenic enlargement/rupture (rare)
  • •Headache
  • •Fatigue

Always consult with a healthcare professional before starting any peptide therapy.